Lupin Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹7,827 Cr +11.1% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
L

Lupin

Q1 FY27

Lupin Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹8,277Cr
+32.1% YoY
+10.7% QoQ
Net profit
₹1,417Cr
+16.1% YoY
−3.5% QoQ
Margin
30%
+2 pp YoY
−3 pp QoQ

What the Q1 FY27 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Price₹1,962
Market cap₹89.7K Cr
P/E15.1

The short version

Europe is expected to grow at a 10%-20% level, with South Africa slightly lower. - Rest of World (ROW) markets also anticipated to continue double-digit growth. - U.S. Lupin expects U.S.

From Lupin's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Moderate growth
  • Europe is expected to grow at a 10%-20% level, with South Africa slightly lower.
  • Rest of World (ROW) markets also anticipated to continue double-digit growth.
  • U.S. sales projected to return to growth trajectory from FY28, building on a base of USD 1.1-1.2 billion in FY27.
  • U.S. portfolio complexity to double in 3-5 years with 50+ planned product launches including exclusive first-to-files, biosimilars, and 505(b)(2) products.
  • India business growing 13.9% YoY, core prescriptions growing 15.1%, outperforming market by 1.1x, targeting 1.2x-1.3x IPM growth.
  • India aims for one-third revenue from innovative products over next 10 years with 60-70 product launches.

2 more points from Lupin's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Lupin said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Lupin has allocated capital for innovation in India, focusing on developing 30-50 assets at a time and aiming for one-third of India revenues from innovative products over 10 years.
  • A small but commercial investment is planned, particularly in the U.S., for the biosimilars business and 505(b)(2) products like Apixaban.
  • Investment is also ongoing in expanding the biosimilars portfolio, specialty acquisitions (e.g., VISUfarma), and complex generics in Europe and the U.S.
  • Incremental investments in key markets are expected to maximize pipeline opportunities, including commercial investments for 505(b)(2) filings.

2 more points from Lupin's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Lupin said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The discussion focuses primarily on revenue growth, product pipeline, market segments, geographic business outlook, and financial performance including margins and investments. Key points relevant to future business outlook include: - Planned launch of 50+ products in the U.S. over the next three years, including 10+ exclusive first-to-files, 5 biosimilars, and 2-3 505(b)(2) products. - Strong pipeline in biosimilars, injectables, respiratory, and specialty products. - Doubling complex generics portfolio in the U.S. over 3-5 years.

2 more points from Lupin's call on order book

Create a free account to keep reading this call

Lupin — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Lupin Q1 FY27 results — key figures

Lupin Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue8,2776,268+32.1%7,475+10.7%
Operating profit (EBITDA)2,4501,727+41.9%2,486-1.4%
Operating margin30%28%+2 pp33%-3 pp
Profit before tax2,0171,416+42.4%1,928+4.6%
Net profit (PAT)1,4171,221+16.1%1,469-3.5%
EPS (₹)30.9526.69+16%31.94-3.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹7.8K Cr, net profit ₹1.2K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Lupin and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Lupin Q1 FY27 results?

Europe is expected to grow at a 10%-20% level, with South Africa slightly lower. - Rest of World (ROW) markets also anticipated to continue double-digit growth. - U.S. Lupin expects U.S.

What is Lupin share price analysis?

Lupin currently shows a below-average growth signal. The stock trades at a P/E of 15.1 with a market cap of ₹89,702 Cr. Investors should review the full earnings analysis for detailed insights.

Is Lupin planning capital expenditure?

Lupin has allocated capital for innovation in India, focusing on developing 30-50 assets at a time and aiming for one-third of India revenues from innovative products over 10 years. - A small but commercial investment is planned, particularly in the U.S., for the biosimilars business and 505(b)(2) products like Apixaban. - Investment is also ongoing in expanding the biosimilars portfolio, specialty acquisitions (e.g., VISUfarma), and complex generics in Europe and the U.S. - Incremental investments in key markets are expected to maximize pipeline opportunities, including commercial investments for 505(b)(2) filings. - Lupin is also making manufacturing investments, such as leveraging domestic U.S.

Keep Lupin on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.